# Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.

> **NCT02101684** · PHASE2 · TERMINATED · sponsor: **Grupo Español de Tumores Huérfanos e Infrecuentes** · enrollment: 10 (actual)

## Conditions studied

- Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors

## Interventions

- **DRUG:** Orteronel 300mg BID

## Key facts

- **NCT ID:** NCT02101684
- **Lead sponsor:** Grupo Español de Tumores Huérfanos e Infrecuentes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2017-01-11
- **Final completion:** 2017-01-11
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Slow recruitment rate
- **Last updated:** 2018-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101684, "Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02101684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*